Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback